STREAM stage 2 showed that two bedaquiline-containing regimens (a 9-month all-oral regimen and a 6-month regimen with 8 weeks of aminoglycoside) had superior efficacy to a 9-month injectable-containing regimen for rifampicin-resistant tuberculosis up to 76 weeks after randomization. Our objective in this follow-up analysis was to assess the durability of efficacy and safety, including mortality, at 132 weeks.
Both of the bedaquiline-containing regimens maintained superiority to the control regimen, without evidence of increased mortality, providing two additional evidence-based treatment options for patients; previous mortality concerns for bedaquiline were not substantiated.
Recent Abstracts
Model Kentucky Ordinance Establishing a County Opioid Abatement Advisory Council
The invisible pain: Gaps in Brazil’s public health system data on Menstrual and…
Exploring the Interface Between Birth Registration and Citizenship Determination: A Scoping Study in…
A dor invisível: lacunas nos dados do SUS sobre dor menstrual e pélvica
Catalyzing Support for CRVS Improvement – Examples from the Data for Health Initiative
A Guide to Designing Contextualized Civil Registration and Vital Statistics E-Learning Courses
Guide to Developing Standard Operating Procedures (SOPs) for Civil Registration Using a Case-Based…
Building Safe and Healthy Communities
Uncovering the Hidden Risks of PM 2.5 Exposure Among School-Aged Children in Jakarta
Strengthening Health Systems to Address Air Pollution in Ethiopia